High-Density Lipoproteins and Their Constituent, Sphingosine-1-Phosphate, Directly Protect the Heart Against Ischemia/Reperfusion Injury In Vivo via the S1P3 Lysophospholipid Receptor

Background— All treatments of acute myocardial infarction are aimed at rapid revascularization of the occluded vessel; however, no clinical strategies are currently available to protect the heart from ischemia/reperfusion injury after restitution of blood flow. We hypothesized that some of the cholesterol transport–independent biological properties of high-density lipoprotein (HDL) implied in atheroprotection may also be beneficial in settings of acute myocardial reperfusion injury. Methods and Results— In an in vivo mouse model of myocardial ischemia/reperfusion, we observed that HDL and its sphingolipid component, sphingosine-1-phosphate (S1P), dramatically attenuated infarction size by ≈20% and 40%, respectively. The underlying mechanism was an inhibition of inflammatory neutrophil recruitment and cardiomyocyte apoptosis in the infarcted area. In vitro, HDL and S1P potently suppressed leukocyte adhesion to activated endothelium under flow and protected rat neonatal cardiomyocytes against apoptosis. In vivo, HDL- and S1P-mediated cardioprotection was dependent on nitric oxide (NO) and the S1P3 lysophospholipid receptor, because it was abolished by pharmacological NO synthase inhibition and was completely absent in S1P3-deficient mice. Conclusions— Our data demonstrate that HDL and its constituent, S1P, acutely protect the heart against ischemia/reperfusion injury in vivo via an S1P3-mediated and NO-dependent pathway. A rapid therapeutic elevation of S1P-containing HDL plasma levels may be beneficial in patients at high risk of acute myocardial ischemia.

[1]  P. Xia.  Letter by Xia regarding article, "High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor". , 2007, Circulation.

[2]  S. Miura,et al.  Newly developed reconstituted high-density lipoprotein containing sphingosine-1-phosphate induces endothelial tube formation. , 2007, Atherosclerosis.

[3]  R. Sabbadini,et al.  Targeting sphingosine-1-phosphate for cancer therapy , 2006, British Journal of Cancer.

[4]  K. Ley,et al.  Sphingosine-1 Phosphate Prevents Monocyte/Endothelial Interactions in Type 1 Diabetic NOD Mice Through Activation of the S1P1 Receptor , 2006, Circulation research.

[5]  P. Linsel-Nitschke,et al.  HDL as a target in the treatment of atherosclerotic cardiovascular disease , 2005, Nature Reviews Drug Discovery.

[6]  W. Weimar,et al.  FTY720, A Novel Immunomodulator: Efficacy and Safety Results from the First Phase 2A Study in de novo Renal Transplantation , 2005, Transplantation.

[7]  Michael D. Davis,et al.  Sphingosine-1-Phosphate Prevents Tumor Necrosis Factor-&agr;–Mediated Monocyte Adhesion to Aortic Endothelium in Mice , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[8]  M. Ezekowitz,et al.  High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. , 2005, European heart journal.

[9]  J. Chun,et al.  Immunomodulator FTY720 Induces eNOS-Dependent Arterial Vasodilatation via the Lysophospholipid Receptor S1P3 , 2005, Circulation research.

[10]  K. Saku,et al.  Correlation of high density lipoprotein (HDL)-associated sphingosine 1-phosphate with serum levels of HDL-cholesterol and apolipoproteins. , 2005, Atherosclerosis.

[11]  B. Lucchesi,et al.  Apolipoprotein A-IMilano and 1-Palmitoyl-2-oleoyl Phosphatidylcholine Complex (ETC-216) Protects the in Vivo Rabbit Heart from Regional Ischemia-Reperfusion Injury , 2004, Journal of Pharmacology and Experimental Therapeutics.

[12]  K. Watson,et al.  Anti-Inflammatory Properties of HDL , 2004, Reviews in Endocrine and Metabolic Disorders.

[13]  O. Schober,et al.  High-Density Lipoprotein Stimulates Myocardial Perfusion In Vivo , 2004, Circulation.

[14]  P. Barter,et al.  Antiinflammatory Properties of HDL , 2004 .

[15]  E. Goetzl,et al.  Sphingosine Kinase Activation Mediates Ischemic Preconditioning in Murine Heart , 2004, Circulation.

[16]  R. Bolli,et al.  Myocardial Protection at a Crossroads: The Need for Translation Into Clinical Therapy , 2004, Circulation research.

[17]  A. Gotto,et al.  HDL Cholesterol and Protective Factors in Atherosclerosis , 2004, Circulation.

[18]  R. Gerszten,et al.  Role of endothelial nitric oxide synthase in endothelial activation: insights from eNOS knockout endothelial cells. , 2004, American journal of physiology. Cell physiology.

[19]  T. Hla,et al.  Point-Counterpoint of Sphingosine 1-Phosphate Metabolism , 2004, Circulation research.

[20]  G. Heusch,et al.  Nitric oxide in myocardial ischemia/reperfusion injury. , 2004, Cardiovascular research.

[21]  G. Assmann,et al.  HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. , 2004, The Journal of clinical investigation.

[22]  L. Ignarro,et al.  Gene transfer of endothelial NO synthase, but not eNOS plus inducible NOS, regressed atherosclerosis in rabbits. , 2004, Cardiovascular research.

[23]  J. Garcia,et al.  Role of sphingosine-1 phosphate in the enhancement of endothelial barrier integrity by platelet-released products. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[24]  M. Hayden,et al.  Restoration of Endothelial Function by Increasing High‐Density Lipoprotein in Subjects With Isolated Low High‐Density Lipoprotein , 2003, Circulation.

[25]  P. Boekstegers,et al.  VEGF165 transfection decreases postischemic NF‐κB‐dependent myocardial reperfusion injury in vivo: role of eNOS phosphorylation , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  G. Franceschini,et al.  High-Density Lipoproteins Protect Isolated Rat Hearts From Ischemia-Reperfusion Injury by Reducing Cardiac Tumor Necrosis Factor-&agr; Content and Enhancing Prostaglandin Release , 2003, Circulation research.

[27]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[28]  B. Berk,et al.  Transactivation of Vascular Endothelial Growth Factor (VEGF) Receptor Flk-1/KDR Is Involved in Sphingosine 1-Phosphate-stimulated Phosphorylation of Akt and Endothelial Nitric-oxide Synthase (eNOS)* , 2002, The Journal of Biological Chemistry.

[29]  P. Hellings,et al.  The Lectin-like Domain of Thrombomodulin Confers Protection from Neutrophil-mediated Tissue Damage by Suppressing Adhesion Molecule Expression via Nuclear Factor κB and Mitogen-activated Protein Kinase Pathways , 2002, The Journal of experimental medicine.

[30]  D. Mazurais,et al.  Cell Type-specific Localization of Human Cardiac S1P Receptors , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[31]  F. Ruschitzka,et al.  High-Density Lipoprotein Restores Endothelial Function in Hypercholesterolemic Men , 2002, Circulation.

[32]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[33]  R. Bolli.  Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. , 2001, Journal of molecular and cellular cardiology.

[34]  M. Ui,et al.  Sphingosine 1-Phosphate May Be a Major Component of Plasma Lipoproteins Responsible for the Cytoprotective Actions in Human Umbilical Vein Endothelial Cells* , 2001, The Journal of Biological Chemistry.

[35]  I. Shiojima,et al.  Sphingosine 1-Phosphate Activates Akt, Nitric Oxide Production, and Chemotaxis through a GiProtein/Phosphoinositide 3-Kinase Pathway in Endothelial Cells* , 2001, The Journal of Biological Chemistry.

[36]  T. Michel,et al.  Sphingosine 1-Phosphate and Activation of Endothelial Nitric-oxide Synthase , 2001, The Journal of Biological Chemistry.

[37]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[38]  M. Ui,et al.  Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. , 2000, The Biochemical journal.

[39]  D. Stengel,et al.  HDLassociated PAF‐AH reduces endothelial adhesiveness in apoE−/− mice , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  Ames,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[41]  J. Gamble,et al.  High Density Lipoproteins (HDL) Interrupt the Sphingosine Kinase Signaling Pathway , 1999, The Journal of Biological Chemistry.

[42]  K. Claffey,et al.  Vascular Endothelial Cell Adherens Junction Assembly and Morphogenesis Induced by Sphingosine-1-Phosphate , 1999, Cell.

[43]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[44]  P. Hansen.  Inflammatory alterations in the myocardial microcirculation. , 1998, Journal of molecular and cellular cardiology.

[45]  J. Gamble,et al.  High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[46]  M. Hori,et al.  Nitric oxide synthase protects the heart against ischemia-reperfusion injury in rabbits. , 1995, The Journal of pharmacology and experimental therapeutics.

[47]  P. Kubes,et al.  Inhibition of nitric oxide production. Mechanisms of vascular albumin leakage. , 1993, Circulation research.

[48]  D. Gordon,et al.  High-density lipoprotein--the clinical implications of recent studies. , 1989, The New England journal of medicine.